Spectrum Pharmaceuticals, Inc.-Product Pipeline Review-2015

Spectrum Pharmaceuticals, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC06953CDB
  • |
  • Pages: 79
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Spectrum Pharmaceuticals, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Spectrum Pharmaceuticals, Inc.-Product Pipeline Review-2015', provides an overview of the Spectrum Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Spectrum Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Spectrum Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Spectrum Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Spectrum Pharmaceuticals, Inc.'s pipeline products

Reasons To Buy

Evaluate Spectrum Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Spectrum Pharmaceuticals, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Spectrum Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Spectrum Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Spectrum Pharmaceuticals, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Spectrum Pharmaceuticals, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Spectrum Pharmaceuticals, Inc. Snapshot 6

Spectrum Pharmaceuticals, Inc. Overview 6

Key Information 6

Key Facts 6

Spectrum Pharmaceuticals, Inc.-Research and Development Overview 7

Key Therapeutic Areas 7

Spectrum Pharmaceuticals, Inc.-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Spectrum Pharmaceuticals, Inc.-Pipeline Products Glance 14

Spectrum Pharmaceuticals, Inc.-Late Stage Pipeline Products 14

Pre-Registration Products/Combination Treatment Modalities 14

Phase III Products/Combination Treatment Modalities 15

Spectrum Pharmaceuticals, Inc.-Clinical Stage Pipeline Products 16

Phase II Products/Combination Treatment Modalities 16

Phase I Products/Combination Treatment Modalities 17

Spectrum Pharmaceuticals, Inc.-Early Stage Pipeline Products 18

Preclinical Products/Combination Treatment Modalities 18

Spectrum Pharmaceuticals, Inc.-Unknown Stage Pipeline Products 19

Unknown Products/Combination Treatment Modalities 19

Spectrum Pharmaceuticals, Inc.-Drug Profiles 20

melphalan 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

apaziquone 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

pralatrexate 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

vincristine sulfate 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Yttritum 90 ibritumomab tiuxetan 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

belinostat 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

lucanthone hydrochloride 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

menadione 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

ortataxel 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

ozarelix 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

SPI-014 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

SPI-1620 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

MTRN-2696 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

SPI-205 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

topotecan hydrochloride liposomal 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

vinorelbine tartrate liposomal 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

rituximab biosimilar 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Spectrum Pharmaceuticals, Inc.-Pipeline Analysis 50

Spectrum Pharmaceuticals, Inc.-Pipeline Products by Target 50

Spectrum Pharmaceuticals, Inc.-Pipeline Products by Route of Administration 52

Spectrum Pharmaceuticals, Inc.-Pipeline Products by Molecule Type 53

Spectrum Pharmaceuticals, Inc.-Pipeline Products by Mechanism of Action 54

Spectrum Pharmaceuticals, Inc.-Recent Pipeline Updates 56

Spectrum Pharmaceuticals, Inc.-Dormant Projects 72

Spectrum Pharmaceuticals, Inc.-Discontinued Pipeline Products 73

Discontinued Pipeline Product Profiles 73

efaproxiral 73

ortataxel 73

RH-1 73

Spectrum Pharmaceuticals, Inc.-Company Statement 74

Spectrum Pharmaceuticals, Inc.-Locations And Subsidiaries 76

Head Office 76

Other Locations & Subsidiaries 76

Appendix 78

Methodology 78

Coverage 78

Secondary Research 78

Primary Research 78

Expert Panel Validation 78

Contact Us 78

Disclaimer 79

List of Tables

Spectrum Pharmaceuticals, Inc., Key Information 6

Spectrum Pharmaceuticals, Inc., Key Facts 6

Spectrum Pharmaceuticals, Inc.-Pipeline by Indication, 2015 8

Spectrum Pharmaceuticals, Inc.-Pipeline by Stage of Development, 2015 10

Spectrum Pharmaceuticals, Inc.-Monotherapy Products in Pipeline, 2015 11

Spectrum Pharmaceuticals, Inc.-Partnered Products in Pipeline, 2015 12

Spectrum Pharmaceuticals, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 13

Spectrum Pharmaceuticals, Inc.-Pre-Registration, 2015 14

Spectrum Pharmaceuticals, Inc.-Phase III, 2015 15

Spectrum Pharmaceuticals, Inc.-Phase II, 2015 16

Spectrum Pharmaceuticals, Inc.-Phase I, 2015 17

Spectrum Pharmaceuticals, Inc.-Preclinical, 2015 18

Spectrum Pharmaceuticals, Inc.-Unknown, 2015 19

Spectrum Pharmaceuticals, Inc.-Pipeline by Target, 2015 51

Spectrum Pharmaceuticals, Inc.-Pipeline by Route of Administration, 2015 52

Spectrum Pharmaceuticals, Inc.-Pipeline by Molecule Type, 2015 53

Spectrum Pharmaceuticals, Inc.-Pipeline Products by Mechanism of Action, 2015 55

Spectrum Pharmaceuticals, Inc.-Recent Pipeline Updates, 2015 56

Spectrum Pharmaceuticals, Inc.-Dormant Developmental Projects,2015 72

Spectrum Pharmaceuticals, Inc.-Discontinued Pipeline Products, 2015 73

Spectrum Pharmaceuticals, Inc., Other Locations 76

Spectrum Pharmaceuticals, Inc., Subsidiaries 77

List of Figures

Spectrum Pharmaceuticals, Inc.-Pipeline by Top 10 Indication, 2015 8

Spectrum Pharmaceuticals, Inc.-Pipeline by Stage of Development, 2015 10

Spectrum Pharmaceuticals, Inc.-Monotherapy Products in Pipeline, 2015 11

Spectrum Pharmaceuticals, Inc.-Partnered Products in Pipeline, 2015 12

Spectrum Pharmaceuticals, Inc.-Pipeline by Top 10 Target, 2015 50

Spectrum Pharmaceuticals, Inc.-Pipeline by Top 10 Route of Administration, 2015 52

Spectrum Pharmaceuticals, Inc.-Pipeline by Top 10 Molecule Type, 2015 53

Spectrum Pharmaceuticals, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Current R&D Portfolio of Spectrum Pharmaceuticals, Inc.; Spectrum Pharmaceuticals, Inc. - Key Therapeutics; Spectrum Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Spectrum Pharmaceuticals, Inc. - News; Spectrum Pharmaceuticals, Inc. - Latest Updates; Spectrum Pharmaceuticals, Inc. - Pipeline; Spectrum Pharmaceuticals, Inc. - Discontinued/Dormant Projects

select a license
Single User License
USD 1500 INR 108255
Site License
USD 3000 INR 216510
Corporate User License
USD 4500 INR 324765



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com